Genetic and molecular profilingof human cancers may in the future enable selection of a tumor subtypesusceptible to PPARγ agonists, as specific genotypes and patternsof nuclear receptor and cofactor expression might predict resistance orresponsiveness to PPARγ signal transduction. The gene discussed is PPARG; the disease is cancer.